High prevalence of *Helicobacter pylori* in saliva demonstrated by a novel PCR assay

C Li, P R Musich, T Ha, D A Ferguson Jr, N R Patel, D S Chi, E Thomas

Abstract

Aims—To investigate the prevalence of *Helicobacter pylori* in the saliva of patients infected with this bacterium.

Methods—A novel polymerase chain reaction (PCR) assay was developed to detect *H pylori* in saliva and gastric biopsy specimens from patients undergoing endoscopy.

Results—Our PCR assay amplified a 417 base pair fragment of DNA from all 21 DNAs derived from *H pylori* clinical isolates but did not amplify DNA from 23 non-*H pylori* strains. Sixty three frozen gastric biopsy and 56 saliva specimens were tested. *H pylori* specific DNA was detected by PCR in all 39 culture positive biopsy specimens and was also identified from another seven biopsy specimens which were negative by culture but positive by histology. *H pylori* specific DNA was identified by PCR in saliva specimens from 30 (75%) of 40 patients with *H pylori* infection demonstrated by culture or histological examination, or both, and in three patients without *H pylori* infection in the stomach.

Conclusion—The results indicate that the oral cavity harbours *H pylori* and may be the source of infection and transmission.

(J Clin Pathol 1995;48:662-666)

Keywords: *Helicobacter pylori*, saliva, PCR.

Helicobacter pylori is now recognised as an important cause of active chronic gastritis in humans, plays a significant pathogenic role in the development and recurrence of gastric and duodenal ulcers,^{1,2} and perhaps gastric cancer.³⁻⁵ The mode of transmission, the natural history and other aspects of the epidemiology of *H pylori* infection are still unclear.

There is some evidence that the mouth may be a reservoir for *H pylori* infection. In two studies from India using conventional microbiological techniques, *H pylori* was present in the dental plaques of 100% of asymptomatic volunteers⁶ and in 98% of dyspeptic subjects.⁷ In a report from Sweden, however, *H pylori* was not recovered by culture from dental plaques or saliva from any of 52 patients who had culture positive gastric biopsy specimens.⁸

Polymerase chain reaction (PCR) protocols have recently been developed to detect *H pylori* in clinical specimens.⁹⁻¹² Using this technique, attempts to detect *H pylori* DNA in dental plaque have been reported recently. From subjects whose gastric biopsy specimens

were culture negative, 13 (93%) of 14 adults¹³ and 11 (58%) of 19 children¹⁴ were positive by PCR. In patients with proven gastric infection, *H pylori* DNA was detected in seven (39%) of 18¹⁵ and in two (13%) of 13 (15%),¹⁶ respectively. As the primers used in these studies were derived from different genes, the results are difficult to evaluate.

We have recently developed a highly sensitive and specific DNA probe from chromosomal DNA of *H pylori*.¹⁷ We have shown that the probe is very useful for typing *H pylori* clinical isolates.^{17,18} Here, we further report the development of a novel PCR assay based on the DNA sequence of our probe (Musich P R, Li C, 1994, unpublished data) and its use in the investigation of the prevalence of *H pylori* in saliva. The results indicate that our PCR assay is a valuable tool for detecting *H pylori* in saliva and could be used to elucidate the mode of transmission of infection.

Methods

SOURCE OF BACTERIAL STRAINS

The *H pylori* strains used in this study included the American Type Culture Collection (ATCC) strain 43629 and 20 *H pylori* isolates from human gastric biopsy specimens.¹⁷

Twenty three strains, including five *Helicobacter* spp, 12 closely related non-*Helicobacter* spp and four urease positive species not closely related to *H pylori*, were used in specificity studies. They included: *H fennelliae* (ATCC 35684); *H cinaedi* (clinical isolate); *H heilmannii* (ATCC 49286); *H felis* (ATCC 49179); *H mustelae* (ATCC 43772); *Campylobacter concisus* (ATCC 33237); *C sputorum* subsp. *sputorum* (ATCC 35980); *C sputorum* subsp. *bubulus* (ATCC 33491); *C jejuni* (two clinical isolates); *C coli* (clinical isolate); *C lari* (Skirrow, E152283); *C upsaliensis* (clinical isolate); *C fetus* subsp. *fetus* (clinical isolate); *C rectus* (VPI 10278B); *Arcobacter cryaerophila* (clinical isolate); *Wolinella succinogenes* (ATCC 29543); *W. subsp. group 2* (VPI 10279); *W. subsp. group 3* (VPI 10296); *Escherichia coli* (ATCC 25922); *Klebsiella pneumoniae* (clinical isolate); *Morganella morganii* (clinical isolate); and *Proteus mirabilis* (clinical isolate). The clinical isolates were obtained from the Clinical Microbiology Laboratory, Department of Microbiology, James H. Quillen College of Medicine, East Tennessee State University, and were isolated and identified by standard microbiological procedures.¹⁹

Department of
Internal Medicine
(Gastroenterology),
James H. Quillen
College of Medicine,
East Tennessee State
University, Johnson
City, Tennessee 37684,
USA

C Li
T Ha
N R Patel
D S Chi
E Thomas

Department of
Biochemistry
P R Musich

Department of
Microbiology
D A Ferguson Jr

Veterans Affairs
Medical Center,
Johnson City,
Tennessee
N R Patel
E Thomas

Correspondence to:
Dr Eapen Thomas, Veterans
Affairs Medical Center
(111D), Johnson City,
TN 37684, USA.

Accepted for publication
1 December 1994

BIOPSY AND SALIVA SPECIMENS

Gastric biopsy specimens were obtained from 63 patients undergoing endoscopic examinations at the Veterans Affairs Medical Center, Johnson City, Tennessee, approved by the Institutional Research Board of East Tennessee State University. All biopsy specimens were cultured as described previously,¹⁷ examined histologically and stored at -70°C . Modified Steiner (silver) stain was used for identification of *H pylori* in histological specimens. Saliva specimens (1–2 ml) were collected from 56 of the 63 patients before undergoing endoscopy. The patients were asked to expectorate the saliva directly into new sterile containers containing digestion buffer (100 mM NaCl, 10 mM Tris-HCl (pH 8.3), 250 mM EDTA, and 1% sodium lauryl sarcosine). The saliva specimens were stored at -70°C .

PREPARATION OF GENOMIC DNA FOR PCR ASSAY

Genomic DNA from *H pylori* isolates and non-*H pylori* strains were prepared from freshly harvested bacterial cells as described previously.¹⁷

Each frozen gastric biopsy specimen was gently washed with TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and then transferred to an Eppendorf tube. The specimens were suspended in 100 μl digestion buffer and 100 μg proteinase K per ml and incubated at 55°C for three hours. The nucleic acids were extracted with an equal volume of phenol chloroform and precipitated with absolute ethanol. The DNA pellets were washed with 75% ethanol and finally resuspended in 50–100 μl TE buffer.

One volume of the digestion buffer and 100 μg proteinase K per ml were added to the saliva samples and incubated at 55°C for three hours. The samples were then processed as for the DNA preparation from gastric biopsy specimens, described earlier.

PCR PRIMERS

Sequence data of the 0.86 kilobase DNA fragment (Musich P R, Li C, 1994, unpublished data) were used to select two 24 base oligonucleotide primers designated EHC-U (5'-CCC TCA CGC CAT CAG TCC CAA AAA-3') and EHC-L (5'-AAG AAG TCA AAA ACG CCC CAA AAC-3'). The oligonucleotides were synthesised at The Johns Hopkins University, School of Hygiene and Public Health, on the Eppendorf Synostat-D DNA Synthesiser and purified by a reverse phase high pressure liquid chromatography method. The expected product of amplification of the target sequence with these primers was 417 base pairs in length.

PCR AMPLIFICATION

Amplification was performed in 50 μl reaction volumes containing the following: 0.5 μM of each primer; 200 μM (each) dATP, dCTP,

dTTP, and dGTP; 1 $\times$ reaction buffer (50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl_2 , and 0.001% w/v gelatin); 1.25 units of Taq polymerase (Perkin-Elmer Cetus, Norwalk, Connecticut, USA); and 2 μl of DNA sample. Thirty cycles of amplification were performed in a DNA thermal cycler (GeneAmp PCR 9600 system, Perkin-Elmer Cetus). Each cycle consisted of a 45 second denaturation step at 94°C , a 30 second annealing step at 59°C and a 45 second extension step at 72°C . The final cycle included an extension step (10 minutes at 72°C) to ensure full extension of the product. Negative reagent control reactions were included in each batch of amplifications and consisted of tubes containing distilled water in place of the DNA samples.

PREPARATION OF DNA PROBE

The 417 base pair fragment was amplified from genomic DNA of *H pylori* type strain ATCC 43629 by PCR with the EHC-U and EHC-L primers and used as the probe in Southern hybridisation. After amplification, the reaction mixtures were electrophoresed in 1.5% agarose gels and the 417 base pair fragments of interest were recovered from an agarose gel by electrophoresis onto DEAE-cellulose membrane (Nytran, NA-45, Schleicher & Schuell, Keene, New Hampshire, USA).²⁰ The DNA probe was labelled with ^{32}P -dCTP (Amersham, Arlington Heights, Illinois, USA) by the Prime-a-Gene labelling system (Promega, Madison, Wisconsin, USA) to a specific activity of $1\text{--}2 \times 10^9$ cpm/ μg DNA.

Figure 1 Agarose gel electrophoresis of the 417 base pair (bp) amplified PCR products from *H pylori* ATCC 436219 (lane 1) and pUC₈ plasmid DNA containing the 0.86 kilobase fragment (lane 2). Lane M contains a pGEM DNA marker (Promega).

SOUTHERN BLOT HYBRIDISATION ANALYSIS

For identification of the amplified products, 10 µl of the PCR reaction was analysed by electrophoresis on 1.5% agarose gels (SeaKem LE Agarose; FMC Products, Rockland, Maine, USA) and the amplified fragments were then transferred from the agarose gel to a nylon membrane (Nytran, Schleicher & Schuell) by standard Southern blotting.²⁰ The membranes were hybridised with the ³²P-dCTP labelled DNA probe at the conditions described previously.¹⁷ The membranes were exposed to Kodak X-Omat XAR-5 film with intensifying screens for one to four hours at -70°C.

Results

DEVELOPMENT OF THE PCR ASSAY

By using the EHC-U and EHC-L primers, our PCR assay successfully amplified the expected product of 417 base pairs in size when either pUC₁₉ plasmid DNA containing 0.86 kilobase insert or genomic DNA from *H. pylori* type strain ATCC 43629 was used as a template (fig 1).

Figure 2 Detection of *H. pylori* in gastric biopsy specimens. The amplified products were analysed by agarose gel electrophoresis (A) and Southern blot hybridisation (B). Lane 1, *H. pylori* ATCC 436219 (positive control); lanes 2–11, gastric biopsy specimens collected from 10 patients; lane 12, PCR negative control; lanes 5 and 10, gastric biopsy specimens from two patients which were negative for *H. pylori* infection on histological examination, culture and PCR.

SENSITIVITY AND SPECIFICITY OF THE PCR ASSAY

The sensitivity of PCR for detection of *H. pylori* sequences was tested by preparing serial dilutions of genomic DNA from *H. pylori* type strain ATCC 43629. As little as 0.1 pg of genomic DNA generated a detectable 417 base pair fragment when 10 µl of PCR reaction mixture was analysed by agarose gel electrophoresis. The sensitivity of the PCR assay for the detection of bacterial cells was also evaluated by using 10-fold dilutions of fresh *H. pylori* (ATCC 43629) bacterial cells. The number of bacterial cells per ml was estimated by means of McFarland nephelometer standards. The cells were then diluted with sterile distilled water and boiled for 15 minutes. PCR assay could detect as few as 10 cells when amplified products were analysed by Southern blot hybridisation. Our PCR assay also detected *H. pylori* specific DNA from all 21 *H. pylori* clinical isolates when the amplified products were examined by agarose gel electrophoresis.

Twenty three genomic DNAs from five *Helicobacter* spp (*H. mustelae*, *H. fennelliae*, *H. cinaedi*, *H. felis*, and *H. heilmanni*), 14 closely related, non-*Helicobacter* spp and four urease positive species not closely related to *H. pylori* were used to test the specificity of our PCR assay. Twenty two of these strains showed no amplified products at an annealing temperature of 59°C when tested by agarose gel electrophoresis and Southern blot hybridisation. One strain (*W. succinogenes*) generated a 500 base pair fragment which was detectable on agarose gel electrophoresis but was not detected by Southern blot hybridisation. When the annealing temperature was increased to 62°C, however, no amplified product was detected from *W. succinogenes* by agarose gel electrophoresis. As *W. succinogenes* is restricted to bovine rumen and is not isolated from humans, use of PCR annealing temperature at 59°C is not epidemiologically significant.

PCR ASSAY OF GASTRIC BIOPSY SPECIMENS

Gastric biopsy specimens obtained from 63 patients were tested by PCR assay, and the results were compared with those of histological examination (modified Steiner stain) and culture. PCR assay detected *H. pylori* specific DNA in all 39 culture positive biopsy specimens. Seven additional biopsy specimens which were negative by culture but positive by histology were also found to contain *H. pylori* specific DNA by PCR. The remaining 17 biopsy specimens which were negative by both histology and culture were also negative by our PCR assay. Figure 2 shows a representative PCR result of the gastric biopsy specimens from 10 patients. Lanes 5 and 10 are PCR negative. The gastric biopsy specimens from these two patients were also negative for *H. pylori* infection as tested by histological examination and culture.

Figure 3 Detection of *H pylori* in saliva specimens. The amplified products were analysed by agarose gel electrophoresis (A) and Southern blot hybridisation (B). Lane 1, *H pylori* ATCC 436219 (positive control); lanes 2–11, saliva specimens collected from the same 10 patients as shown in fig 2; lane 12, PCR negative control; lane 4, a PCR negative saliva specimen from a patient whose gastric biopsy specimen was positive for *H pylori* infection; lanes 5 and 10, PCR negative saliva specimens from two patients whose gastric biopsy specimens were also negative for *H pylori* infection.

PCR ASSAY OF SALIVA SPECIMENS

Saliva specimens were collected from 56 patients and tested by PCR. Forty of the 56 patients were shown to have *H pylori* infection by culture, PCR and/or histological examination of their gastric biopsy specimens. The PCR assay detected *H pylori* sequences in saliva specimens from 30 of these 40 patients and in saliva specimens from three other patients without gastric *H pylori* infection. Figure 3 shows a representative PCR result of the saliva specimens from the same 10 patients as shown in fig 2. Lanes 5 and 10 are PCR negative for the saliva specimens from two patients whose gastric biopsy specimens were also negative for *H pylori* as demonstrated by histological examination, culture and PCR assay. The negative PCR result in the lane 4 is from the saliva specimen of a patient whose gastric biopsy specimen was positive by culture and PCR assay.

Discussion

In this study a novel PCR assay for detecting *H pylori* DNA in clinical specimens was developed using two 24 base oligonucleotide primers based on the sequence of the 0.86 kilobase fragment of chromosomal DNA of *H pylori* (Musich P R, Li C, 1994, unpublished data).

Sixty three gastric biopsy specimens were tested for *H pylori* specific DNA by our PCR assay. Good correlation between our PCR assay and culture/staining methods indicates that the PCR assay is sufficiently specific and sensitive to use for the detection of *H pylori* in clinical specimens. Hammar *et al*¹² reported that their PCR assay detected the presence of *H pylori* in four biopsy specimens which were negative by culture. However, no information about the presence of *H pylori* on histological staining was given. Clayton *et al*¹⁰ reported that *H pylori* was detected by PCR in 15 of 23 clinical gastric biopsy samples. Only seven of these samples were positive for *H pylori* on culture and microscopy. Mapstone *et al*¹⁶ found that eight patients with histologically normal gastric biopsy specimens had *H pylori* DNA on PCR. It is difficult to compare these findings because of the use of different primers, PCR protocols and sampling techniques.

Valentine *et al*⁹ and Zwet *et al*²¹ showed that the results of detection of *H pylori* by culture were comparable with those of their PCR assay. In our study the PCR assay identified *H pylori* from an additional seven biopsy specimens which were negative on culture but positive on histology. It is obvious that the PCR assay is more sensitive (46/63) than culture (39/63), which depends on the presence of viable organisms.

Recently, we have successfully isolated *H pylori* from the saliva of one patient whose gastric biopsy specimen was positive on culture.²² This prompted us to use PCR to investigate the prevalence of *H pylori* in saliva. Our PCR assay identified *H pylori* specific DNA in 75% (30 of 40) of patients with proven gastric *H pylori* infection. Hammar *et al*¹² reported a 47% (nine of 19) detection rate of *H pylori* specific DNA by PCR in saliva specimens from patients with proven *H pylori* infection and Mapstone *et al*¹⁶ found 31% (three of 31) of saliva specimens to be positive on PCR. Our PCR assay had a higher rate of detection of *H pylori* DNA in saliva (75%) than these reports. This may be explained by our finding that the 0.86 kilobase DNA fragment used to develop our PCR assay may exist as multiple copies in the genomic DNA of *H pylori*.²² Other possible explanations may be that (1) saliva specimens were directly collected into the digestion buffer in our protocols and (2) the whole saliva sample was used for extraction of DNA rather than pellets from saliva.

H pylori DNA was identified by PCR in saliva specimens from three patients whose gastric biopsy specimens were negative for *H pylori* on histological examination, culture and PCR. It is unlikely that these specimens were contaminated by extraneous *H pylori* DNA for the following reasons. Firstly, the saliva specimens were collected by asking the patients to ex-

pectorate directly into new sterile containers before undergoing endoscopy. Secondly, we performed sample collection, DNA extraction, pre-PCR preparation, and PCR amplification in separate rooms. Finally, we performed our PCR assay procedures using a minimum number of steps, used disposable tips and tubes, and regularly included negative controls with each test. There was no clear correlation between gastric symptoms and the presence of *H. pylori* DNA in the oral cavity. It is possible that oral colonisation by *H. pylori* may precede gastric infection. The possibility of such oral colonisation is supported by the observation of *H. pylori* in the dental plaque of children at a much higher frequency than had been previously reported in the literature.¹⁴

Whether the *H. pylori* DNA we have detected in saliva represents long term colonisation or sporadic reinfection from gastric reflux is not clear. However, *H. pylori* has been recovered by culture from dental plaques^{6,23} and saliva.²² *H. pylori* DNA has also been identified by PCR in dental plaques¹³⁻¹⁵ and saliva^{12,16} of patients with and without *H. pylori* infection in several other studies. These findings suggest that the mouth may be a permanent reservoir for the organism and a source of both infection and transmission.

This project was supported in part by a grant from Glaxo Research Institute. We thank Betty Barnett, Department of Microbiology, for her technical skill in preparing media and reagents for this study. We thank Guha Krishnaswamy, Department of Internal Medicine, for technical advice on PCR.

- Graham DY. *Campylobacter pylori* and peptic ulcer disease. *Gastroenterology* 1989;96:615-25.
- Taylor DN, Blaser MJ. The epidemiology of *Helicobacter pylori* infection. *Epidemiol Rev* 1991;13:42-59.
- Forman D, Sitas F, Newell DG, Stacey AR, Boreham J, Peto R, et al. Geographic association of *Helicobacter pylori* antibody prevalence and gastric cancer mortality in rural China. *Int J Cancer* 1990;46:608-11.
- Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, et al. Association between infection with *Helicobacter pylori* and risk of gastric cancer: evidence from a prospective investigation. *BMJ* 1991;302:1302-5.
- Parsonnet J, Vandersteen D, Goates J, Sibley RK, Pritikin J, Chang Y. *Helicobacter pylori* infection in intestinal- and diffuse-type gastric adenocarcinomas. *J Natl Cancer Inst* 1991;83:640-3.
- Majmudar P, Shah SM, Dhunjibhoy KR, Desai HG. Isolation of *Helicobacter pylori* from dental plaque in healthy volunteers. *Indian J Gastroenterol* 1990;4:271-2.
- Desai HG, Gill HH, Shankaran K, Mehta PR, Prabhu SR. Dental plaque: a permanent reservoir of *Helicobacter pylori*. *Scand J Gastroenterol* 1991;26:1205-8.
- Bernander S, Dalen J, Gastrin B, Hedenborg L, Lamke LO, Ohn R. Absence of *Helicobacter pylori* in dental plaques in *Helicobacter pylori* positive dyspeptic patients. *Eur J Clin Microbiol Infect Dis* 1993;12:282-5.
- Valentine JL, Arthur RR, Mobley HLT, Dick JD. Detection of *Helicobacter pylori* by using the polymerase chain reaction. *J Clin Microbiol* 1991;29:689-95.
- Ho SA, Hoyle JA, Lewis FA, Secker AD, Cross D, Mapstone NP, et al. Direct polymerase chain reaction test for detection of *Helicobacter pylori* in humans and animals. *J Clin Microbiol* 1991;29:2543-9.
- Clayton CL, Kleanthous H, Coates PJ, Morgan DD, Tabaqchali S. Sensitive detection of *Helicobacter pylori* by using polymerase chain reaction. *J Clin Microbiol* 1992;30:192-200.
- Hammer M, Tyszkiewicz T, Wadstrom T, O'Toole PW. Rapid detection of *Helicobacter pylori* in gastric biopsy material by polymerase chain reaction. *J Clin Microbiol* 1992;30:54-8.
- Olsson K, Wadstrom T, Tyszkiewicz T. *H. pylori* in dental plaques [letter]. *Lancet* 1993;341:956-67.
- Banatvala N, Lopez CR, Owen RJ, Hurtado A, Abdi Y, Davies GR, et al. Use of the polymerase chain reaction to detect *Helicobacter pylori* in the dental plaque of healthy and symptomatic individuals. *Microbial Ecology in Health and Disease* 1994;7:1-8.
- Nguyen AMH, Engstrand L, Genta RM, Graham DY, El-Zaatari FAK. Detection of *Helicobacter pylori* in dental plaque by reverse transcription-polymerase chain reaction. *J Clin Microbiol* 1993;31:783-7.
- Mapstone NP, Lynch DAF, Lewis FA, Axon ATR, Tompkins DS, Dixon MF, et al. Identification of *Helicobacter pylori* DNA in the mouths and stomachs of patients with gastritis using PCR. *J Clin Pathol* 1993;46:540-3.
- Li C, Ferguson DA Jr, Ha T, Chi DS, Thomas E. A highly specific and sensitive DNA probe derived from chromosomal DNA of *Helicobacter pylori* is useful for typing *H. pylori* isolates. *J Clin Microbiol* 1993;31:2157-62.
- Li C, Ferguson DA Jr, Ha T, Chi DS, Thomas E. Evaluation of a rRNA gene probe and a DNA probe for typing *Helicobacter pylori* clinical isolates [abstract]. *Gastroenterology* 1993;104:A133.
- Balows A, Hausler WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ. *Manual of clinical microbiology*. 5th edn. Washington DC: American Society for Microbiology, 1991.
- Sambrook J, Fritsch EF, Maniatis T. *Molecular cloning: a laboratory manual*. 2nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989.
- Zwet AA van, Thijs JC, Kooistra-Smid AMD, Schirm J, Snijder JAM. Sensitivity of culture compared with that of polymerase chain reaction for detection of *Helicobacter pylori* from antral biopsy samples. *J Clin Microbiol* 1993;31:1918-20.
- Ferguson DA Jr, Li C, Patel NR, Mayberry WR, Chi DS, Thomas E. Isolation of *Helicobacter pylori* from saliva. *J Clin Microbiol* 1993;31:2802-4.
- Krajen S, Fuksa M, Anderson J, Kempston J, Boccia A, Petrea C, et al. Examination of human stomach biopsies, saliva, and dental plaque for *Campylobacter pylori*. *J Clin Microbiol* 1989;31:1397-8.